Transdermal opioids as front line treatment of moderate to severe cancer pain: A systemic review

Davide Tassinari, Fabrizio Drudi, Marta Rosati, Marco Maltoni

Research output: Contribution to journalArticle

Abstract

Background: To assess the role of transdermal opioids as a front-line approach to moderate to severe cancer pain.Methods: A systematic review of the literature was performed by two authors. An analysis of the level of evidence and risk/benefit ratio was performed for all of the selected trials. A combined analysis of the included studies to assess the level of evidence, risk/benefit ratio and strength of the recommendations was performed to determine the place of transdermal opioids in the treatment of cancer when compared with oral morphine.Results: Thirteen papers were included in the analysis. The level of evidence was considered low for transdermal opioids (without distinction between transdermal fentanyl and transdermal buprenorphine) or transdermal fentanyl, and very low for transdermal buprenorphine. The risk/benefit ratio was considered uncertain for both transdermal opioids (fentanyl and buprenorphine) considered together and transdermal fentanyl or buprenorphine alone. The strength of the final recommendations (using the GRADE system) was weak negative for transdermal opioids (transdermal fentanyl plus transdermal buprenorphine) and transdermal fentanyl, and strong negative for transdermal buprenorphine.Conclusions: The use of slow release oral morphine probably remains the preferred approach for these patients, with the use of transdermal opioids to be reserved for selected patients.

Original languageEnglish
Pages (from-to)478-487
Number of pages10
JournalPalliative Medicine
Volume25
Issue number5
DOIs
Publication statusPublished - Jul 2011

Fingerprint

Buprenorphine
Fentanyl
Opioid Analgesics
Odds Ratio
Morphine
Therapeutics
Cancer Pain
Neoplasms

Keywords

  • administration
  • cutaneous
  • Neoplasm
  • opioids
  • pain

ASJC Scopus subject areas

  • Medicine(all)
  • Anesthesiology and Pain Medicine

Cite this

Transdermal opioids as front line treatment of moderate to severe cancer pain : A systemic review. / Tassinari, Davide; Drudi, Fabrizio; Rosati, Marta; Maltoni, Marco.

In: Palliative Medicine, Vol. 25, No. 5, 07.2011, p. 478-487.

Research output: Contribution to journalArticle

Tassinari, Davide ; Drudi, Fabrizio ; Rosati, Marta ; Maltoni, Marco. / Transdermal opioids as front line treatment of moderate to severe cancer pain : A systemic review. In: Palliative Medicine. 2011 ; Vol. 25, No. 5. pp. 478-487.
@article{69c12512b5994211b627d08079eb54db,
title = "Transdermal opioids as front line treatment of moderate to severe cancer pain: A systemic review",
abstract = "Background: To assess the role of transdermal opioids as a front-line approach to moderate to severe cancer pain.Methods: A systematic review of the literature was performed by two authors. An analysis of the level of evidence and risk/benefit ratio was performed for all of the selected trials. A combined analysis of the included studies to assess the level of evidence, risk/benefit ratio and strength of the recommendations was performed to determine the place of transdermal opioids in the treatment of cancer when compared with oral morphine.Results: Thirteen papers were included in the analysis. The level of evidence was considered low for transdermal opioids (without distinction between transdermal fentanyl and transdermal buprenorphine) or transdermal fentanyl, and very low for transdermal buprenorphine. The risk/benefit ratio was considered uncertain for both transdermal opioids (fentanyl and buprenorphine) considered together and transdermal fentanyl or buprenorphine alone. The strength of the final recommendations (using the GRADE system) was weak negative for transdermal opioids (transdermal fentanyl plus transdermal buprenorphine) and transdermal fentanyl, and strong negative for transdermal buprenorphine.Conclusions: The use of slow release oral morphine probably remains the preferred approach for these patients, with the use of transdermal opioids to be reserved for selected patients.",
keywords = "administration, cutaneous, Neoplasm, opioids, pain",
author = "Davide Tassinari and Fabrizio Drudi and Marta Rosati and Marco Maltoni",
year = "2011",
month = "7",
doi = "10.1177/0269216311404274",
language = "English",
volume = "25",
pages = "478--487",
journal = "Palliative Medicine",
issn = "0269-2163",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Transdermal opioids as front line treatment of moderate to severe cancer pain

T2 - A systemic review

AU - Tassinari, Davide

AU - Drudi, Fabrizio

AU - Rosati, Marta

AU - Maltoni, Marco

PY - 2011/7

Y1 - 2011/7

N2 - Background: To assess the role of transdermal opioids as a front-line approach to moderate to severe cancer pain.Methods: A systematic review of the literature was performed by two authors. An analysis of the level of evidence and risk/benefit ratio was performed for all of the selected trials. A combined analysis of the included studies to assess the level of evidence, risk/benefit ratio and strength of the recommendations was performed to determine the place of transdermal opioids in the treatment of cancer when compared with oral morphine.Results: Thirteen papers were included in the analysis. The level of evidence was considered low for transdermal opioids (without distinction between transdermal fentanyl and transdermal buprenorphine) or transdermal fentanyl, and very low for transdermal buprenorphine. The risk/benefit ratio was considered uncertain for both transdermal opioids (fentanyl and buprenorphine) considered together and transdermal fentanyl or buprenorphine alone. The strength of the final recommendations (using the GRADE system) was weak negative for transdermal opioids (transdermal fentanyl plus transdermal buprenorphine) and transdermal fentanyl, and strong negative for transdermal buprenorphine.Conclusions: The use of slow release oral morphine probably remains the preferred approach for these patients, with the use of transdermal opioids to be reserved for selected patients.

AB - Background: To assess the role of transdermal opioids as a front-line approach to moderate to severe cancer pain.Methods: A systematic review of the literature was performed by two authors. An analysis of the level of evidence and risk/benefit ratio was performed for all of the selected trials. A combined analysis of the included studies to assess the level of evidence, risk/benefit ratio and strength of the recommendations was performed to determine the place of transdermal opioids in the treatment of cancer when compared with oral morphine.Results: Thirteen papers were included in the analysis. The level of evidence was considered low for transdermal opioids (without distinction between transdermal fentanyl and transdermal buprenorphine) or transdermal fentanyl, and very low for transdermal buprenorphine. The risk/benefit ratio was considered uncertain for both transdermal opioids (fentanyl and buprenorphine) considered together and transdermal fentanyl or buprenorphine alone. The strength of the final recommendations (using the GRADE system) was weak negative for transdermal opioids (transdermal fentanyl plus transdermal buprenorphine) and transdermal fentanyl, and strong negative for transdermal buprenorphine.Conclusions: The use of slow release oral morphine probably remains the preferred approach for these patients, with the use of transdermal opioids to be reserved for selected patients.

KW - administration

KW - cutaneous

KW - Neoplasm

KW - opioids

KW - pain

UR - http://www.scopus.com/inward/record.url?scp=79959916310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959916310&partnerID=8YFLogxK

U2 - 10.1177/0269216311404274

DO - 10.1177/0269216311404274

M3 - Article

C2 - 21708854

AN - SCOPUS:79959916310

VL - 25

SP - 478

EP - 487

JO - Palliative Medicine

JF - Palliative Medicine

SN - 0269-2163

IS - 5

ER -